HCS assays indicated that inhibition of LARS2 and ZNF19 contributed to decreased tumor cell proliferation, suggesting a molecular mechanism behind melittin’s anti-hepatoma activity [36]. The gene discussed is ZNF19; the disease is hepatocellular carcinoma.